Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.

• Adjuvant high-dose interferon alfa-2b improves relapse-free survival (RFS) in patients with high-risk melanoma, although benefits in overall survival are uncertain. Because of the toxic effects of high-dose regimens, intermediate doses are being explored. We investigated whether adjuvant therapy with intermediate-dose interferon alfa-2b for 1 or 2 years would improve outcomes in patients with stage IIB-IIC or III resected cutaneous melanoma.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

Adolescent

Adult

Aged

Antineoplastic Agents

therapeutic use

Chemotherapy

Adjuvant

methods

Disease-Free Survival

Dose-Response Relationship

Drug

Female

Humans

Interferon Alfa-2b

therapeutic use

Male

Melanoma

drug therapy

Middle Aged

Risk Factors

Time Factors

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)